Self-assembled peptide–poloxamine nanoparticles enable in vitro and in vivo genome restoration for cystic fibrosis
暂无分享,去创建一个
Joseph Rosenecker | Peter Braubach | Carsten Rudolph | Burkhard Tümmler | Yadhu Kumar | J. Rosenecker | F. Stanke | B. Tümmler | C. Rudolph | G. Hasenpusch | Z. Ivics | P. Braubach | Shan Guan | S. Glage | Frauke Stanke | Silke Hedtfeld | S. Lienenklaus | A. Munder | Antje Munder | Silke Glage | Longgui Zhang | Stefan Lienenklaus | Anja Schultze | Günther Hasenpusch | Wiebke Garrels | Csaba Miskey | Sarah M. Johler | Zoltan Ivics | W. Garrels | Longgui Zhang | Yadhu Kumar | Silke Hedtfeld | S. Guan | C. Miskey | Anja Schultze | Csaba Miskey
[1] Y. Kong,et al. Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium , 2015, Nature Communications.
[2] J. Marshall,et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis , 1990, Cell.
[3] S. L. Hyatt,et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. , 2004, Human gene therapy.
[4] S. Hart,et al. Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery. , 2011, Biomaterials.
[5] P. Palange,et al. Cystic fibrosis , 2016, The Lancet.
[6] Gregg A. Duncan,et al. Barriers to inhaled gene therapy of obstructive lung diseases: A review. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[7] Wei Chen,et al. Retargeting sleeping beauty transposon insertions by engineered zinc finger DNA-binding domains. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[8] Daniel G. Anderson,et al. Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.
[9] Randall J. Platt,et al. Therapeutic genome editing: prospects and challenges , 2015, Nature Medicine.
[10] Justin Hanes,et al. Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. , 2011, Angewandte Chemie.
[11] D. Escande,et al. Negatively charged self-assembling DNA/poloxamine nanospheres for in vivo gene transfer. , 2004, Nucleic acids research.
[12] P. Hackett. Integrating DNA vectors for gene therapy. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[13] S. E. Barker,et al. Targeted Gene Delivery to Human Airway Epithelial Cells with Synthetic Vectors Incorporating Novel Targeting Peptides Selected by Phage Display , 2004, Journal of drug targeting.
[14] Hans Clevers,et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids , 2013, Nature Medicine.
[15] D. Meyerholz,et al. Origins of cystic fibrosis lung disease. , 2015, The New England journal of medicine.
[16] David K. Meyerholz,et al. Disruption of the CFTR Gene Produces a Model of Cystic Fibrosis in Newborn Pigs , 2008, Science.
[17] David R. Liu,et al. Efficient Delivery of Genome-Editing Proteins In Vitro and In Vivo , 2015 .
[18] A. Zoso,et al. Animal and model systems for studying cystic fibrosis. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[19] J. Keith Joung,et al. Efficient Delivery of Genome-Editing Proteins In Vitro and In Vivo , 2014, Nature Biotechnology.
[20] J. S. St. George,et al. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications. , 2001, Human gene therapy.
[21] Theresa A. Storm,et al. Large-Scale Molecular Characterization of Adeno-Associated Virus Vector Integration in Mouse Liver , 2005, Journal of Virology.
[22] B. Singh,et al. Hybrid nonviral/viral vector systems for improved piggyBac DNA transposon in vivo delivery. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[23] Elias Fattal,et al. Parameters affecting organization and transfection efficiency of amphiphilic copolymers/DNA carriers. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[24] J. Gustafson,et al. Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.
[25] Steve Cunningham,et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial , 2015 .
[26] Y. C. Chai,et al. Preclinical and clinical advances in transposon-based gene therapy , 2017, Bioscience reports.
[27] Z. Ivics,et al. Specifically integrating vectors for targeted gene delivery: progress and prospects , 2017 .
[28] Mauro Ferrari,et al. Principles of nanoparticle design for overcoming biological barriers to drug delivery , 2015, Nature Biotechnology.
[29] J. Rosenecker,et al. Nebulisation of IVT mRNA Complexes for Intrapulmonary Administration , 2015, PloS one.
[30] A. Doherty,et al. Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis , 2016, Thorax.
[31] J. Rosenecker,et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice , 2011, Nature Biotechnology.
[32] A. Concheiro,et al. Poloxamine-based nanomaterials for drug delivery. , 2010, Frontiers in bioscience.
[33] K. Jensen,et al. In vitro and ex vivo strategies for intracellular delivery , 2016, Nature.
[34] F. Stanke,et al. Spontaneous rescue from cystic fibrosis in a mouse model , 2006, BMC Genetics.
[35] Shu Wang,et al. Self-assembled ternary complexes of plasmid DNA, low molecular weight polyethylenimine and targeting peptide for nonviral gene delivery into neurons. , 2007, Biomaterials.
[36] Y. Kong,et al. Correction of F508del CFTR in airway epithelium using nanoparticles delivering triplex-forming PNAs , 2015, Nature communications.
[37] J. Riordan,et al. Characterization of wild-type and deltaF508 cystic fibrosis transmembrane regulator in human respiratory epithelia. , 2005, Molecular biology of the cell.
[38] Z. Izsvák,et al. Gene Therapy with the Sleeping Beauty Transposon System. , 2017, Trends in genetics : TIG.
[39] Thomas Ferkol,et al. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. , 2007, Human gene therapy.
[40] A. Trapani,et al. Nanocomplexes for gene therapy of respiratory diseases: Targeting and overcoming the mucus barrier. , 2015, Pulmonary pharmacology & therapeutics.
[41] Samuel K. Lai,et al. Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[42] Hans Clevers,et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. , 2013, Cell stem cell.
[43] J. Darcourt,et al. Evaluation of tetrafunctional block copolymers as synthetic vectors for lung gene transfer. , 2015, Biomaterials.
[44] Gregg A. Duncan,et al. The Mucus Barrier to Inhaled Gene Therapy. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.
[45] R. Hartmann,et al. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[46] Samuel K Lai,et al. PEGylation for enhancing nanoparticle diffusion in mucus☆ , 2017, Advanced drug delivery reviews.
[47] J. S. Suk,et al. Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy , 2015, Proceedings of the National Academy of Sciences.
[48] S. Dowdy. Overcoming cellular barriers for RNA therapeutics , 2017, Nature Biotechnology.
[49] Michael P Boyle,et al. The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. , 2009, Biomaterials.
[50] B. Pitard,et al. Relationships between the physicochemical properties of an amphiphilic triblock copolymers/DNA complexes and their intramuscular transfection efficiency , 2006, Nucleic acids research.
[51] Hao Yin,et al. Delivery technologies for genome editing , 2017, Nature Reviews Drug Discovery.
[52] Daniel G. Anderson,et al. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. , 2014, Nature nanotechnology.
[53] Ciaran M. Lee,et al. Correction of the ΔF508 Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Gene by Zinc-Finger Nuclease Homology-Directed Repair , 2012, BioResearch open access.